Evaluation of the deleted in malignant brain tumor 1 protein expression and DNA methylation profile in rheumatoid arthritis patients

Background: Rheumatoid arthritis (RA) is a chronic, autoimmune disease that progressively leads to joint destruction and functional disability which eventually affects the quality of life of the people suffering from it. Deleted in malignant brain tumor 1 (DMBT1) role has been explored in progression of Sjögren's syndrome (SS) and other autoimmune diseases, whereas it has yet to be reported in RA. In this study, we have analyzed and evaluated the expression of DMBT1 protein and the dmbt1 genes' methylation status in healthy volunteers, RA, and SS patients. Methods: In the present investigation, the case–control study of 25 healthy volunteers and 17 RA- and 10 SS-confirmed patients was performed. Results: It was observed that the concentration of DMBT1 protein in saliva decreases in both the disease conditions compared to healthy volunteers, while methylation status of dmbt1 gene was low in both patient cohorts in comparison to the healthy controls. Conclusion: Results obtained from this study indicate that DMBT1 protein has the potential to qualify as a specific salivary biomarker as identified in RA and SS patients. DMBT1 protein can therefore be explored further as a noninvasive tool for diagnosis and prognosis.

[1]  Vana Vukić,et al.  Beyond the guidelines management of juvenile idiopathic arthritis: a case report of a girl with polyarticular disease refractory to multiple treatment options and Leri Weill syndrome , 2021, BMC Pediatrics.

[2]  A. Surdacka,et al.  Salivary Biomarkers for Diagnosis of Inflammatory Bowel Diseases: A Systematic Review , 2020, International journal of molecular sciences.

[3]  Laura E Dedmon.  The genetics of rheumatoid arthritis. , 2020, Rheumatology.

[4]  A. Khayat,et al.  Identifying novel genetic alterations in pediatric acute lymphoblastic leukemia based on copy number analysis , 2020, Molecular Cytogenetics.

[5]  H. Park,et al.  Dysbiotic oral microbiota and infected salivary glands in Sjögren’s syndrome , 2020, PloS one.

[6]  P. Vescovi,et al.  Salivary biomarkers for diagnosis of systemic diseases and malignant tumors. A systematic review , 2020, Medicina oral, patologia oral y cirugia bucal.

[7]  Huanhai Liu,et al.  DMBT1 has a protective effect on allergic rhinitis. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  Dexiang Zhang,et al.  DMBT1 suppresses progression of gallbladder carcinoma through PI3K/AKT signaling pathway by targeting PTEN , 2019, Bioscience, biotechnology, and biochemistry.

[9]  Chunhe Zhang.  The protective role of DMBT1 in cervical squamous cell carcinoma , 2019, The Kaohsiung journal of medical sciences.

[10]  H. Moutsopoulos,et al.  Primary versus Secondary Sjögren Syndrome: Is It Time To Reconsider These Terms? , 2019, The Journal of Rheumatology.

[11]  D. Yakimenko.  SOME FEATURES OF THE RELATIONSHIP BETWEEN PATHOGENETIC MECHANISMS OF HYPOSALIVATION IN RHEUMATOID ARTHRITIS AND SJOGREN'S SYNDROME , 2018, Likarska sprava.

[12]  J. Park,et al.  Deleted in malignant brain tumor 1 is a novel prognostic marker in colorectal cancer. , 2018, Oncology reports.

[13]  L. Bravo,et al.  Increased expression of deleted in malignant brain tumors (DMBT1) gene in precancerous gastric lesions: Findings from human and animal studies , 2017, Oncotarget.

[14]  A. Poustka,et al.  The scavenging capacity of DMBT1 is impaired by germline deletions , 2017, Immunogenetics.

[15]  L. Criswell,et al.  2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts , 2017, Arthritis & rheumatology.

[16]  R. Jonsson,et al.  Sjögren syndrome , 2016, Nature Reviews Disease Primers.

[17]  E. Veerman,et al.  Complement activation by salivary agglutinin is secretor status dependent , 2015, Biological chemistry.

[18]  A. Shahane,et al.  The epidemiology of Sjögren’s syndrome , 2014, Clinical epidemiology.

[19]  Jun S. Liu,et al.  Genetics of rheumatoid arthritis contributes to biology and drug discovery , 2013 .

[20]  James J. Farrell,et al.  Salivary Biomarkers: Toward Future Clinical and Diagnostic Utilities , 2013, Clinical Microbiology Reviews.

[21]  J. Zhao,et al.  Characteristics of Sjögren's syndrome in rheumatoid arthritis. , 2013, Rheumatology.

[22]  Wei Wang,et al.  DNA methylome signature in rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[23]  H. Haga,et al.  A study of the prevalence of sicca symptoms and secondary Sjögren's syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile , 2012, International journal of rheumatic diseases.

[24]  J. Imura,et al.  DMBT1 is a novel gene induced by IL‐22 in ulcerative colitis , 2011, Inflammatory bowel diseases.

[25]  N. Karlsson,et al.  Deleted in Malignant Brain Tumors-1 Protein (DMBT1): A Pattern Recognition Receptor with Multiple Binding Sites , 2010, International journal of molecular sciences.

[26]  U. Holmskov,et al.  Review: Gp-340/DMBT1 in mucosal innate immunity , 2010, Innate immunity.

[27]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[28]  U. Holmskov,et al.  Isolation and Characterization of a New Member of the Scavenger Receptor Superfamily, Glycoprotein-340 (gp-340), as a Lung Surfactant Protein-D Binding Molecule* , 1997, The Journal of Biological Chemistry.

[29]  J. Rundegren,et al.  Characterization of a salivary agglutinin reacting with a serotype c strain of Streptococcus mutans. , 1983, European journal of biochemistry.